• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles Benzodioxoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles

Recent Advances in the Application of 6-(Bromomethyl)-4-chloro-1,3-dioxaindane (CAS: 864152-57-8) in Chemical Biology and Pharmaceutical Research

The compound 6-(bromomethyl)-4-chloro-1,3-dioxaindane (CAS: 864152-57-8) has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile reactivity and potential applications in drug discovery and development. This heterocyclic compound, featuring a bromomethyl functional group, serves as a valuable intermediate in the synthesis of more complex molecules, particularly in the construction of indane-based scaffolds. Recent studies have explored its utility in medicinal chemistry, where it has been employed as a key building block for the development of novel therapeutic agents targeting various diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 6-(bromomethyl)-4-chloro-1,3-dioxaindane in the synthesis of potent kinase inhibitors. The bromomethyl group's reactivity allowed for efficient functionalization, enabling researchers to introduce diverse pharmacophores at this position. This approach led to the discovery of several compounds with nanomolar inhibitory activity against clinically relevant kinases, highlighting the compound's importance in structure-activity relationship (SAR) studies. The research team noted that the chloro substituent at the 4-position contributed significantly to the compounds' metabolic stability, addressing a common challenge in kinase inhibitor development.

In the field of antibiotic development, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the incorporation of 6-(bromomethyl)-4-chloro-1,3-dioxaindane into novel quinolone hybrids. These hybrids exhibited enhanced activity against drug-resistant bacterial strains, with the indane moiety improving membrane penetration and target binding. The study's molecular modeling analyses suggested that the unique spatial arrangement of the dioxaindane ring system contributes to optimal binding interactions with bacterial topoisomerase IV, providing a structural basis for further optimization.

Beyond its applications in small molecule drug discovery, 6-(bromomethyl)-4-chloro-1,3-dioxaindane has shown promise in chemical biology tools development. A 2024 ACS Chemical Biology paper detailed its use in creating activity-based probes for studying cysteine proteases. The electrophilic bromomethyl group served as an effective warhead for covalent modification of active site cysteines, while the dioxaindane core provided the necessary stability and fluorescence properties for detection. This application opens new possibilities for target engagement studies and inhibitor screening in protease research.

The synthetic accessibility of 6-(bromomethyl)-4-chloro-1,3-dioxaindane has also been a focus of recent research. A 2023 Organic Process Research & Development article described an improved, scalable synthesis route with enhanced yield and purity. The optimized procedure addressed previous challenges in regioselective bromination and purification, making the compound more readily available for pharmaceutical applications. Process analytical technology (PAT) was employed to ensure consistent quality, meeting the stringent requirements for Good Manufacturing Practice (GMP) production.

Looking forward, the unique structural features of 6-(bromomethyl)-4-chloro-1,3-dioxaindane continue to inspire innovative applications. Current research directions include its incorporation into PROTACs (proteolysis targeting chimeras) and other targeted protein degradation strategies, where its compact yet functionalizable structure offers advantages in linker design. Additionally, its potential in radiopharmaceutical development is being explored, leveraging the bromine atom for isotopic substitution with radiohalogens for diagnostic and therapeutic applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)